News

News
JNJ Press releases

Big Pharma’s Billion-Dollar Scramble to Invest in Start-ups to Fuel Innovation

Read full story
JNJ Press releases

Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer

Read full story
In the media

What J&J gets out of JLABS incubators

Read full story
In the media

Special Report Mental health: Brain scans and DNA tests personalise mental healthcare

Read full story